Stock analysts at StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of GLMD stock opened at $9.35 on Monday. Galmed Pharmaceuticals has a fifty-two week low of $2.73 and a fifty-two week high of $23.80. The stock’s fifty day moving average price is $4.11 and its two-hundred day moving average price is $4.20. The company has a market cap of $47.17 million, a PE ratio of -3.90 and a beta of 0.67.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its quarterly earnings data on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- Energy and Oil Stocks Explained
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How to Invest in Blue Chip Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
